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r Ltd. This is an open access articl1. Introduction
Kavanagh demonstrated in the early 1950s that several fungal
species of the genus Pleurotus produced substances that inhibit the
activity of Staphylococcus aureus. Further to this, the antibacterial
substance produced by Pleurotus mutilus (Clitopilus scyphoides) and
Pleurotus passeckerianus (Clitopilus passeckerianus) was isolated in
crystalline form and named pleuromutilin.1,2
Structural elucidation studies were ﬁrst published in 1952, with
Anchel correctly describing the molecular formula of pleuromutilin
(C22H34O5) and correctly assigning three of the ﬁve oxygen atoms
as two non-phenolic hydroxyl groups and one hindered carbonyl
group.3 The remaining two oxygen atomswere tentatively assigned
to a lactone ring; this was later corrected, and shown to be the ester
functionality at C14. Independent work by Birch at the University ofe under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e69306912Manchester4,5 and Arigoni at the Swiss Federal Institute of Tech-
nology6 culminated in the publication of the full and correct
structure of (þ)-pleuromutilin (1) (Fig. 1) and a proposed bio-
synthetic pathway, thus characterising pleuromutilin as the glycolic
ester of the diterpene (þ)-mutilin (2).Fig. 1. Structure and numbering of (þ)-pleuromutilin.The numbering of pleuromutilin described by Arigoni has be-
come convention throughout pleuromutilin chemistry is shown in
Fig. 1. For simplicity this systemwill be used throughout this report.
The ever increasing emergence of multi-drug-resistant micro-
organisms has led to the World Health Organisation (WHO) issuing
renewed pleas for action to be taken against antimicrobial re-
sistance.7 The development of new antibiotics has not kept pace
with demand; for example, new cases of multi-drug-resistant tu-
berculosis alone account for around 150,000 deaths annually.7
Since the publication of the structure and activity of pleuro-
mutilin, much synthetic effort has been focused on the synthesis of
analogues with increased activity and a more favourable pharma-A B
C
Fig. 2. Pleuromutilin derivatives: A. veterinary antibiotics; B. human topical antibiotic; C. unlicensed.cokinetic proﬁle. A handful of compounds are widely used in vet-
erinary medicine and a single analogue has been licensed for
topical use on humans. It was recently announced that BC-3781will
enter Phase III clinical trials and may offer the ﬁrst systemic pleu-
romutilin antibiotic for human use.8e12 All of the compounds either
licensed or in clinical trials vary only in the C14 side chain. Despite
this a wealth of chemistry, including complex structural modiﬁca-
tions of the core, has been investigated. Total synthesis, however,
presents the only tool for major re-structuring of the pleuromutilin
core and several groups have attempted to gain synthetic access to
the pleuromutilin core, with three total syntheses now reported.
2. Synthetic manipulation of pleuromutilin
This section of the review catalogues the synthetic manipula-
tions of pleuromutilin, which will be presented in the followingsections: selective functionalisation of the C14 hydroxyl, synthesis
of metabolites and similar compounds, modiﬁcation of the core,
modiﬁcation at C12 andmodiﬁcation at C13.Whilst this report does
not aim to capture every chemical transformation performed on
pleuromutilin or its derivatives, it will provide a useful guide to thereactivity of this structurally intriguing, densely functionalised and
biologically important natural product.
2.1. Modiﬁcation at C14
All of the pleuromutilin analogues currently used in veterinary
(Fig. 2A) or human (Fig. 2B) medicine vary only in the C14 side
chain, furthermore they have sulfur at C22 followed by a two- or
three-carbon linker before a basic nitrogen functionality. More re-
cently azamulin was not progressed beyond Phase I clinical trials
due to poor water solubility; BC-3781, developed at Nabriva, is
however progressing through clinical trials (Fig. 2C).Alternative analogues at C14 have been investigated including
carbamate and acyl carbamate linkers. In this section the aim is to
consider strategies and approaches to analogues of pleuromutilin
and not repeat the excellent and extensive patent and structur-
eeactivity relationship (SAR) reviews on the C14 side chain.13e24
C14 Acyloxy derivatives of mutilin have been prepared, most
commonly by activation of the primary alcohol of pleuromutilin
(C22) as a tosylate 9a (R¼p-tol), followed by substitution with
a thiol (X¼S),25e56 amine (X¼NH)52,57,58 or alcohol (X¼O)43e45,59,60
to form 10 (Scheme 1A). This is the general procedure used for the
synthesis of tiamulin (3)61e63 and valnemulin (4)64e70 (Fig. 2A).
Alternatively the mesylate 9b (R¼Me) was also susceptible to
substitution by a thiol (X¼S)59,71e74 or amine (X¼NH).75 Retapa-
mulin (5) and a number of other analogues were synthesised by an
alternate but similar approach: mesylpleuromutilin 9b (R¼Me) was
substituted with thioacetic acid to give 10 (XR0¼SAc) and treatment
Scheme 1. Selective functionalisation at C22 of pleuromutilin. Reagents: (A) a. 9a, R¼p-tol, TsCl, NaOH, 98%, 9b, R¼Me, MsCl, Et3N, quant; b. R0XH, base (Et3N or NaOH or NaOEt). (B)
c. KI, 87%; d. R0XH, NaOH.
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e6930 6913of 10 with tropine-3-mesylate in the presence of ethylenediamine
cleaved the acetate and gave retapamulin (5) (Fig. 2B).76 The
stepwise strategy has also been reported whereby treatment of 10
(XR0¼SAc) with ethylenediamine afforded pleuromutilin thiol 10
(XR0¼SH), which could itself substitute a number of
mesylates.71,77e79
In an approach to rapidly investigate a number of pleuromutilin
nucleoside conjugates, click chemistry was employed; tosylpleur-
omutilin 9a was substituted with sodium azide to form 10
(XR0¼N3), which underwent click chemistry with a range of nu-
cleoside derived alkynes to form 1,2,3-triazole analogues of pleu-
romutilin.80,81 The azide 10 (XR0¼N3) has also been reduced to give
aminopleuromutilin 10 (XR0¼NH2), which was converted to a range
of analogues.59 Further activation of the C22 position in tosyl-
pleuromutilin 9a by conversion to the bromide or iodide 11 has also
been reported (Scheme 1B). In these cases the halide has been
substituted with a thiol (X¼S), amine (X¼NH2) or alcohol (X¼O) to
give 10.27,28,40,56,60,82
The modiﬁcation of pleuromutilin is desirable as there is no
need for protecting group chemistry. On the other hand, selec-
tive functionalisation of the C14 hydroxyl in mutilin is less
straightforward as the C11 hydroxyl is considerably more
reactive.
Berner demonstrated inversion of the stereochemistry at C4
with a concomitant 1,5-hydride shift from C11 to C3 to form 12
(Scheme 2), known colloquially as 4-epi-mutilin (vide infra, Scheme
12).83 This compound has only one hydroxyl (at C14) and can
therefore undergo reaction under a range of conditions to form C14
analogues of mutilin.Scheme 2. 1,5-Hydride shift protection of C11 hydroxyl. Reagents: (A) a. CH(OMe)3, H2SO4, 9
or py, triphosgene. (C) f. NaOCN, TFA.4-epi-Mutilin has been used to form acyl analogues of pleuro-
mutilin such as 14 by treatment with the required acid chloride59,84
(Scheme 2A). Conversion of 13 to the desired mutilin analogue 14
was achieved using ZnCl2 and HCl. This restored the C4 stereo-
chemistry and a 1,5-hydride shift from C3 to C11 reformed the
carbonyl and hydroxyl, respectively.
A number of groups have reported access to C14 carbamate
analogues of pleuromutilin 14 (R¼NHR0) through carbon-
ochloridate 15 (Scheme 2B). Compound 15 has been prepared by
treatment of 4-epi-mutilin 12 with trichloromethyl chlor-
oformate,85 phosgene,86 or triphosgene.87,88 Compound 15 has then
been converted to several different carbamates by reaction with
various amines. Once again treatment with ZnCl2 and HCl com-
pletes the synthesis of these analogues.
An alternate approach to C14 carbamates through 4-epi-mutilin
12was reported in 2007.89,90 Treatment of 12with sodium cyanate
and triﬂuoroacetic acid lead to the formation of 4-epi-mutilin-14-
carbamate 16, which was acylated to give a range of acetylcarba-
mates. Yang has since reported a one-pot procedure for the syn-
thesis of 4-epi-mutilin-14-acetylcarbamates using silver(I) cyanate
and an acid chloride.42,88,91e95 Further optimization to a process
route was also reported and in that case an acetyl isocyanate was
preformed and coupled with 4-epi-mutilin.96
Alternatively, selective protection of the C11 hydroxyl of mutilin
followed by reaction of the C14 hydroxyl has been reported. Strat-
egies involving bis-acylation (C11 and C14) followed by mild cleav-
age of the C14 acetatewere ﬁrst reported.92 However, more recently
the triﬂuoroacetyl group has been employed as an easily cleaved
protecting group that can be selectively installed at C11 (Scheme 3).5%; b. NaOH/MeOH, 97%; c. RC(O)Cl; d. ZnCl2, HCl. (B) e. trichloromethyl chloroformate
Scheme 3. Triﬂuoroacetate protection of the C11 hydroxyl. Reagents: a. TFAA, py, or TFA-im; b. RC(O)Cl, Et3N, DMAP; c. base (NaOH or Et3N).
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e69306914Treatment of mutilin with TFAA and pyridine (Discovery route)
or with triﬂuoroacetylimidazole (Process route) provided the C11
triﬂuoroacetyl mutilin 17, which has been shown to take part in
several ester-forming reactions.58,97 The advantage of this strategy
is that simple treatment of 18 with mild base will cleave the C11
triﬂuoroacetyl group and afford the desired pleuromutilin analogue
14. Intermediate 17 has also been used in a range of carbamate and
acyl carbamate forming reactions, previously described with 4-epi-
mutilin (Scheme 2).42,88,92,93,97
Yang has reported the synthesis and biological data for a series
of water-soluble phosphate prodrugs of pleuromutilin analogues,
the most promising example bears the phosphate at a phenolic
hydroxyl on a C14 carbamate side chain; however, Yang also re-
ported an example of a C11 phosphate prodrug of a C14 carbamate
pleuromutilin analogue. Both of these compounds were shown to
be suitably soluble and stable in aqueous buffer, and the phenolic
phosphate was metabolised to the active drug and exhibited
comparable antibacterial activity to vancomycin in a mouse
model.42,96
In 2001 Takle and co-workers at SmithKline Beecham reported
an approach to C14 amido mutilin derivative 22 (Scheme 4).85
Treatment of diacetylmutilin 19 with potassium tert-butoxide
afforded the cyclopropyl mutilin derivative 20, which proved
largely resistant to further reaction. However, treatment of 20with
sodium azide in DMF at 150 C led to the formation of 21, albeit in
very low yield. Reduction of the azide in 21 proceeded with con-
comitant reduction of the C12 vinyl. This was followed by conver-
sion of the C14 amine to an amide and saponiﬁcation of the C11
acetate to give 22. The intermediate C14 amino mutilin has also
been used in the synthesis of C14 acylurea analogues. Takle and co-
workers have shown that these two C14 amino derived analogues
have dramatically reduced antibacterial properties and therefore
this analogue family was not investigated further.Scheme 4. Synthesis of C14 amino mutilin analogues by Takle. Reagents: a. t-BuOK, 32%; b. NaN3, 5%; c. H2, Pd/C; d. PhCH2C(O)Cl, Et3N, 68% (two steps); e. NaOH, 35%.Many C14 analogues of pleuromutilin (>3000) have been syn-
thesised, however, only three have made it through clinical trials to
medicinal use and only one for use on humans (topical).
2.2. Synthesis of metabolites and similar compounds
The metabolism of pleuromutilin has been mainly attributed to
cytochrome P450 (CYP) dependant hydroxylation at either C2 (23)
or C8 (24) of the tricyclic core (Scheme 5). These compounds are
almost entirely devoid of biological activity.98,99 Metabolite 25 wasalso isolated and is the product of de-ethylation of the tiamulin side
chain. This compound exhibits around 25% of the activity of tia-
mulin, metabolites that are active, but exhibit activity at a lower
level than the parent antibiotic would be expected to select for
antimicrobial resistance.100
Several researchers have investigated synthetic access to the
metabolites of pleuromutilin and also to compounds potentially
blocked to metabolism. Hanson has investigated the bio-
transformation of pleuromutilin and mutilin using CYPs in whole
cell cultures.99,101 Treatment of (þ)-pleuromutilin (1) with Cun-
ninghamella echinulata SC 16162, a ﬁlamentous fungus, provided
(2R)-hydroxy pleuromutilin 26 (Scheme 6A). Interestingly, the
opposite epimer 27 is obtained upon treatment of (þ)-mutilin (2)
under the same conditions (Scheme 6B). Hanson also reported
access to a separable mixture of 2-, 7- and 8-hydroxy mutilins 27,
28 and 29, respectively, by treatment of mutilin with gram positive
bacterium Streptomyces griseus SC 1754 or SC 13971, and pre-
parative quantities of 28 and 29 were available by this method. Of
course these biotransformations could not be carried out on pleu-
romutilin, due to its antibiotic nature.
Several studies have investigated the products of bio-
transformation of mutilin: C8 hydroxymutilin derivatives (28) have
been used to synthesise a number of analogues including a C8 keto
derivative. However, the vast majority of these analogues have been
shown to exhibit no antibacterial activity.102e104
In an attempt to block the metabolism of pleuromutilin de-
rivatives Yang reported the synthesis of (2S)-ﬂuoro mutilin de-
rivatives (32) from 2-diazomutilin 31 (Scheme 7). Upon installation
of a suitable C14 side chain, these compounds showed appreciable
activity with respect to the parent compound. Yang also reported
access to (2S)-hydroxy mutilin derivatives 35; as expected, con-
siderable erosion of the activity was observed for these
compounds.5,91,97,105,106Yang employed Berner’s diazomutilin derivative 31 for the
synthesis of both the ﬂuoro and hydroxyl derivatives. Treatment of
pleuromutilin with methylformate and sodium methoxide led to
activation of C2 by formation of the 1,3-dicarbonyl 30. Upon
treatment with tosyl azide in Et3N the a-diazoketo derivative 31
was formed and ﬂuorination upon treatment with HF/pyridine
formed 32. a-Diazoketone 31 was also treated with dichloroacetic
acid to afford, after hydrolysis, the hydroxyl derivative 35.
The reactivity of the vinyl moiety at C12 can prove problematic
for some transformations of pleuromutilin. Egger and
Scheme 6. Biotransformation of pleuromutilin and mutilin by Hanson. Conditions: (A) and (B) a. Cunninghamella echinulata SC 16162. (C) b. Streptomyces griseus SC 1754 and SC
13971.
Scheme 7. Synthesis of (2S)-ﬂuoro and hydroxy mutilin derivatives by Yang. Reagents: a. methyl formate, NaOMe; b. Et3N, TsN3, 44%; c. HF-py, 47%; d. Cl2CHCO2H, 58%; e. 4-
(acetoxy)benzoyl chloride, AgOCN, 73%, XR¼NHC(O)C6H4OAc; f. KOH, EtOH, 70%, XR0¼NHC(O)C6H4OH.
Scheme 5. Metabolites formed in pig liver microsomes.
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e6930 6915Reinshagen61,107 reported that several methyl, ethyl derivatives,
such as 36 (Scheme 8), had largely unchanged bioactivity with
respect to the methyl, vinyl parents. Modiﬁcations of C12, ﬁrst
described by Arigoni and Birch during structural elucidation
studies will be discussed later. However 19,20-
dihydropleuromutilin 36 has proved a useful starting material in
the preparation of some analogues.
As part of a vast pleuromutilin programme at Sandoz, Berner
described the synthesis of (2R)-hydroxy mutilin derivative 39 by
selective reduction of 1,2-diketopleuromutilin 38, which in turn
was available through Mannich reaction of pleuromutilin followed
by ozonolysis of 37. The same intermediate (38) was employed en
route to analogues in which the C3 carbonyl was transposed to C2
(41, Scheme 8). Isomerisation of 39 under basic conditions provided
40, acetylation of 40 and careful reduction then afforded mutilin
derivative 41.108
Axten has since reported a somewhat simpliﬁed procedure for
the synthesis of diacetylated 41. Treatment of diacetyl mutilinderivative 42 with sodium borohydride reduced the C3 ketone se-
lectively to the (3S)-hydroxy derivative 43. Upon mesylation and
elimination, 44was formed in high yield and oxidised selectively at
the allylic position using catalytic dirhodium(II) caprolactamate, to
give 45 in 40% yield; the corresponding allylic alcohol was also
isolated in 47% yield. Dissolving metal reduction afforded the de-
sired cyclopentanone product in 64% yield but as a mixture of the
diacetate (20%) and the monoacetates109 (Scheme 9).
Simple and scalable access to 2-hydroxy mutilin was not avail-
able until 2008 when Wang reported a Rubottom oxidation pro-
cedure (Scheme 10). Treatment of mutilin with lithium
hexamethdisilazide and TMSCl selectively afforded the kinetic silyl
enol ether 46, which was oxidised using m-CPBA. Commonly
NaHCO3 is employed to buffer the Rubottom oxidation, however, in
this case issues of over-oxidation and irreproducibility were re-
ported. This was partially due to the inhomogeneity of the reaction
mixture. Buffering the reaction with acetic acid and pyridine of-
fered improved yields and high reproducibility on kilogramme
Scheme 9. Rhodium-mediated allylic oxidation to form C2-ketomutilin derivatives by Axten. Reagents: a. NaBH4, 98%; b. MsCl, Et3N, 87%; c. Rh2(cap)4, t-BuOOH, K2CO3, 40%.
Scheme 10. Scalable synthesis of (2S)-hydroxymutilin by Wang. Reagents: a. TMSCl, LiHMDS; b. m-CPBA, AcOH/py; c. HCl, 78% (three steps).
Scheme 8. Synthesis of (2R)-hydroxy and 2-keto mutilin derivatives by Berner. Reagents: a. paraformaldehyde, Me2NH$HCl, HCl, 49%; b. xylene, D, 71%; c. O3; Me2S, 67%; d. 10% Pd/
C, H2, 79%; e. KOH, (Bu)4NHSO4, 76%; f. Ac2O, py, 74%; g. Li, NH3, 59%. R¼C(O)CH2OH.
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e69306916scale. Acidic hydrolysis of the remaining silyl ethers led to the
formation of 27 in 78% yield after crystallisation.110
As described above, several strategies aimed at mimicking na-
ture in gaining oxidative access to C2 have been developed, how-
ever, the seemingly unactivated positions of metabolism on
pleuromutilin derivatives (C7 and C8) have provided more of
a challenge. Biotransformation has provided preparative access to
metabolites for the investigation of C7 and C8 oxidised analogues of
pleuromutilin and more recently the group of White has accessed
C7 oxidised analogues.
White has developed a method for regio- and stereoselective
oxidation of unactivated CeH bonds in a range of complex mole-
cules, including pleuromutilin derivative 48 (Scheme 11). Oxidation
using catalytic Fe-(S,S)-PDP proceeded at C7; the (7S)-hydroxy
compound 49 was formed in 42% yield, with the keto product 50
isolated in 20% yield and 24% starting 48 recovered.111,112Scheme 11. Iron-mediated oxidation at C7 by White. Reagents: a. Fe2.3. Modiﬁcation of the core
The unique and sterically conﬁned 5,6,8-tricyclic core of pleu-
romutilin is susceptible to alkyl and hydride shifts under certain
conditions; the outcome can include inversion of stereochemistry
or ring expansion or contraction. Some of these transformations
have been observed as undesired by-products in reactions and
some have offered valuable preparative access to mutilin
derivatives.
In 1981 Berner reported conditions for the inversion of stereo-
chemistry at C4; this afforded the 5,6-trans ring junction. The
transformation proceeded in almost quantitative yield with a con-
comitant 1,5-hydride shift between C11 and C3 to afford 4-epi-
pleuromutilin 51, bearing a carbonyl at C11 and a methoxyl at C3.
Most interestingly, treatment of 51 with a Lewis acid initiated the
reverse reaction to reform pleuromutilin (Scheme 12).83-(S,S)-PDP, AcOH, H2O2, R¼C(O)CH2OH, 49 42%, 50 20%, 48 24%.
Scheme 12. Inversion of conﬁguration at C4 and 1,5-hydride shift to form 51 by Berner.
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e6930 6917The reversibility of this process renders 4-epi-pleuromutilin 51
and also 4-epi-mutilin exciting alternative structures for the syn-
thesis of a wealth of analogues; C3 is now protected, the reactivity
of C11 is entirely altered (hydroxyl to carbonyl) and steric argu-
ments have changed. 4-epi-Mutilin has been used in the synthesis
of a range of C12, C13 (vide infra) and C14 (vide supra) mutilin
derivatives.
Amongst other interesting modiﬁcations to the core, Birch
reported a contraction of the eight-membered ring upon activa-
tion of the C11 hydroxyl as a leaving group (Scheme 13).5 This
reaction offered access to a novel 5,6,7-tricyclic ring system 53.
Birch also reported exhaustive ozonolysis of 53 to form 54 as
a mixture of diastereoisomers. Whilst these compounds may have
interesting bioactivity, this transformation has also been observed
as an undesired pathway during the synthesis of pleuromutilin
analogues.Scheme 13. PCl5-mediated eight-membered ring contraction by Birch. Reagents: a. PCl5, 49%; b. O3, H2O2, 34%.Many analogues of pleuromutilin (including tiamulin) are
accessed by activation of the C22 hydroxyl, as a mesylate or tosy-
late, and then substitution by a thiol (vide supra, Scheme 1). Se-
lective mesylation of pleuromutilin can be achieved (primary C22
over secondary C11), however, any C11 mesylated pleuromutilin
that is formed rapidly undergoes ring contraction to form com-
pounds such as 53.71
A group at Bristol-Myers Squibb required a large quantity of the
differentially protected pleuromutilin 56 for a discovery project.
MOM ether 56 is available in high yield by treatment of 55 with
dimethoxymethane and P4O10 (Scheme 14A). Use of a large excess
of P4O10 and extended reaction times led to the formation of by-
products 57 and 58 (Scheme 14B).113,114Scheme 14. P4O10-mediated eight-membered ring expaSpringer proposes that both 57 and 58 are formed through
oxonium ion 59 (Scheme 15); initial cyclisation to form tetrahy-
dropyran 60 was followed by migration of C11 to form the trans-
fused tetrahydrofuran 61. Subsequent loss of Ha led to the external
alkene 62, which incorporated a second equivalent of methyl(-
methylene)oxonium and after loss of Hb formed 58. Alternatively
initial loss of Hb afforded the internal alkene 57.
Birch also observed the autoxidation of diacetoxymutilin using
potassium tert-butoxide and tert-butanol to afford a ring cleaved
ketoacid, similar to 64 (Scheme 16). Under the conditions employed
by Birch the C11 acetate was hydrolysed, this was followed by
a transannular hydride shift from C11 to C4 to afford an 11-keto-4-
hydroxy derivative, which proceeded to form a d-lactone by cycli-
sation of the C4 hydroxyl with the pendant carboxylic acid.5 This
chemistry has since been optimised by Springer on 56, to afford
differentially protected ketoacid 64 in 70% yield. Some of these 6,8-bicyclic systems, exempliﬁed by 65, have shown promising activity
against Streptococcus pneumonia A49585.105
In an attempt to block metabolism, Berner at Sandoz prepared
4,6,8-tricyclic mutilin derivatives from 68 (Scheme 17). 2-
Diazomutilin 66 underwent efﬁcient photo-Wolff rearrangement
to give 67 in 77% yield. Following acetylation to give 68, treatment
with lead(IV) acetate in benzene and pyridine gave a mixture of
the arylated and acetoxy products 69 and 70, respectively. Acetate
70 was then simply converted into the 4,6,8-mutilin analogue
72.115
Modiﬁcation of the pleuromutilin core has offered access to
alternative tricyclic and bicyclic analogues, some of which have
been shown to possess interesting biological activity. This suggestsnsion by Springer. Reagents: a. CH2(OMe)2, P4O10.
Scheme 15. Proposed mechanism for the expansion of the eight-membered ring by Springer.
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Scheme 16. Oxidative cleavage of the ﬁve-membered ring by Springer. Reagents: a. t-BuOK, t-BuOH, O2, 70%.
Scheme 17. Light mediated ﬁve-membered ring contraction by Berner. Reagents: a. 10% Pd/C, H2; b. methyl formate, NaOMe; c. Et3N, TsN3, 44%; d. hy, 77%; e. Ac2O, py, DMAP, 80%; f.
C6H6, py, Pb(OAc)4, 69 34%, 70 24%; g. NaHCO3, 53%; h. CrO3, 87%.
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e69306918that further investigation of pleuromutilin-inspired tricyclic com-
pounds with alternate ring sizes may offer breakthroughs in the
search for improved pleuromutilin-inspired antibacterials.
2.4. Modiﬁcation at C12
Another handle for the modiﬁcation of pleuromutilin is the
C19e20 oleﬁn at C12. Indeed, one of the ﬁrst reactions reportedScheme 18. Reduction ofon pleuromutilin was the dissolving metal reduction with lith-
ium in methanol and ammonia, resulting in reduction of the C3
ketone and the C12 vinyl motif to give 73 (Scheme 18).5,6 Of
course, catalytic hydrogenation of the oleﬁn has since been re-
ported as an approach to 19,20-dihydromutilin derivatives such
as 74.74 C12 Methyl, ethyl compounds of this type were shown to
have largely unaltered activity with respect to their parent
compounds.61,107the C12 vinyl motif.
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e6930 6919Alternatively, thevinyl group is susceptible to oxidation; Birchand
Arigoni both reported ozonolysis of this group in C11 ketomutilin 75.
Treatment of the intermediate peroxideswith hydrogenperoxide led
to the carboxylic acid, which underwent decarboxylation under
thermal conditions to give 76 (albeit in low yield) (Scheme 19).5,6
Birch went on to report that under basic conditions the enolate of
theC11 carbonyl can takepart in aldol chemistrywith theC3 carbonyl
to form the tetracyclic compound 77.5Scheme 19. Removal of the C12 vinyl by Birch. Reagents: a. O3; H2O2; b. D, 36%; c. KOH,
56%.The process of vinyl cleavage has since been revisited by
Berner115 and later by Takadoi at Kyorin Pharmaceutical Co.
Ltd.,60,116,117 for the synthesis of pleuromutilin analogues. Both in-
vestigated this chemistry using 4-epi-mutilin derivatives (51 and
81) (vide supra, Scheme 12), thus protecting the C3 carbonyl from
unwanted aldol reactions. Berner employed ozonolysis to the al-
dehyde 78 and decarbonylation under basic conditions to give 79
(Scheme 20A). Berner demonstrated that 79 was selectively alky-
lated at C12 from the back face with ethyl bromide, after deproto-
nation with NaH, in 78% yield and that the glycolate ester at C14 of
79 could be modiﬁed to give the tiamulin side chain. Either directly
or following modiﬁcation, 79 was converted to 80 (or derivatives
thereof) thus restoring the natural stereochemistry of
pleuromutilin.Scheme 20. Removal of the C12 vinyl by (A) Berner and (B) Takadoi. Reagents: (A) a. O3; AcOH; Na2S2O3, 82%; b. NaOH/MeOH, 95%; c. ZnCl2, HCl, 88%. (B) a. OsO4, NMO, 95%; b.
K2CO3, 87%; c. KHMDS, R0X. R0X¼MeSTs, 85 98%. R0X¼CH^CCH2Br, 84 quant.Using dihydroxylation and then base mediated fragmentation,
Takadoi provided an alternate route to a similar 12-devinyl mutilin
derivative 83 (Scheme 20B). Takadoi installed a number of groups
at C12, including the propargyl group by alkylation with propargyl
bromide to give 84; whilst an interesting derivative in its own right,
the C12 propargyl also offers opportunity for further functionali-
sation. Takadoi also reported the addition of methyl para-toluene-
thiolsulfonate to form the 12-thiomethyl derivative 85. All of
Takadoi’s derivatives were then furnished with a suitable C14 side
chain and the pleuromutilin stereochemistry restored (ZnCl2 and
HCl) before biological evaluation.60,116,117
In an approach to serine protease inhibitors, Kaura at Glax-
oSmithKline developed a Curtius rearrangement approach to C12
amino mutilin derivative 92 (Scheme 21).118 The approach began
with a 1,5-hydride shift dehydroxylation, ﬁrst reported by Birch,5 to
give 87. Dihydroxylation and oxidative cleavage was followed byoxidation under Jones conditions to give the carboxylic acid 88,
which after activation as the acid chloride was treated with sodium
azide to form the acyl azide 89. Curtius rearrangement took place in
reﬂuxing benzene and the resultant isocyanate was hydrolysed to
give a C12methyl, amino derivative of which 90 is the acetyl amide.
Deprotection and oxidation afforded the desired diketone 92 (17%
yield) and a mixture of epoxide by-products.
As part of the total synthesis of pleuromutilin by Boeckman,
Springer developed a route to the late stage intermediate 96 by
degradation of natural pleuromutilin (Scheme 22). Protected
mutilin derivative 93 underwent ozonolysis and further oxidation
to afford the carboxylic acid 94, which could be eliminated in
modest yield either using mercury(II) oxide and iodine or lead(IV)
acetate to afford 95. Further ozonolysis of which afforded the ke-
tone 96 in sufﬁcient quantities to investigate installation of the
quaternary stereocentre at C12 (vide infra, Scheme 35).119
Zard developed exciting methodology for direct addition to the
C12 vinyl of pleuromutilin in the absence of protecting groups.120
Treatment of pleuromutilin with a range of xanthates and
dilauroyl peroxide (DLP) led to addition of the alkyl xanthate across
the oleﬁn to give 97 in moderate to good yields. Whilst Zard sug-
gested that the xanthate in 97may offer a useful handle for further
functionalisation, he also reported two procedures for its removal.
Treatment of 97with DLP or n-Bu3SnH gave 98. The use of both DLP
and n-Bu3SnH gave similar yields, however, DLP may be preferable
for the synthesis of medicinal chemistry as tin is avoided
(Scheme 23).
Hartwig has reported an iridium-catalysed process for H/D ex-
change in vinyl groups and has demonstrated its functional group
tolerance with a number of complex natural products. Brief expo-
sure of tiamulin (3) to catalyst 101 in benzene-d6 led to selectivelabelling of the trans hydrogen to give 99 with only a small per-
centage of exchange of the cis hydrogen observed (100)
(Scheme 24).121
Exploitation of the reactivity of the C12 vinyl group of mutilin
has provided access to a range of novel C12 modiﬁed derivatives.
Furthermore an appreciation that the reduction product has largely
unchanged bioactivity has allowed the use of C12 methyl, ethyl
derivatives in chemistry that would be incompatible with the
presence of an oleﬁn.
2.5. Modiﬁcation at C13
Introduction of nitrogen functionality at C13 of pleuromutilin
was ﬁrst reported by Berner; thermal decomposition of the satu-
rated C14 carbonazidate 103 resulted in formation of 104 in modest
yield as a single undeﬁned diastereoisomer (Scheme 25).122 Berner
Scheme 22. Synthesis of C12 keto mutilin derivatives by Springer. Reagents: a. O3; (MeO)3P, 90%; b. H2NSO3H, NaClO2, 70%; c. HgO, I2, CCl4, 17e25%; d. Pb(OAc)4, benzene, py, 26%; e.
O3; (MeO)3P (c then e 14% (two steps)).
Scheme 23. Radical addition of xanthates to the C12 vinyl group of pleuromutilin by Zard.
Scheme 24. Iridium-catalysed H/D exchange at C20 of tiamulin by Hartwig. Reagents: a. 101, C6D6, 10 min, D incorporation 97%, 99/100, 93:7.
Scheme 21. Synthesis of a diketone serine protease inhibitor by Kaura. Reagents: a. POCl3, py; b. NaIO4, OsO4, 78%; c. Jones oxidation, 75%; d. (COCl)2, DMF; e. NaN3; f. benzene, D; g.
HCl; h. Ac2O, 36% (ﬁve steps); i. NaOH, 72%; j. NaIO4, RuCl3, CCl4, 17%.
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e69306920reported conversion of 104 to a C13 primary amine analogue of
pleuromutilin, however, this required seven steps. Alternatively
104 was converted to 105 by treatment with ZnCl2 and HCl; thus
restoring the pleuromutilin stereochemistry and C3 carbonyl.
In 2011 Uccello at Pﬁzer reinvestigated the C13 amido mutilin
derivative 107 (Scheme 26). 4-epi-Mutilin 12 was treated withsodium cyanate to form carbamate 16, which was used to in-
vestigate direct CeH amidation.123 Regio- and stereoselective
amidation was achieved using silver(III) nitrate and 2,4,6-tri-tert-
butylpyridine to form 106 in 72% yield. As expected, treatment with
ZnCl2 and HCl restored the pleuromutilin structure and stereo-
chemistry to give 107. Attempts to hydrolyse the oxazolidinone in
Scheme 26. AgNO3-catalysed amidation of C13 in a mutilin derivative by Uccello. Reagents: a. CH(OMe)3, MeOH, H2SO4; b. NaOH, MeOH, 65% (two steps); c. NaOCN, TFA, 86%; d.
AgNO3, t-Bu3py, 72%; e. ZnCl2, HCl, 62%; f. HCl, 100 C, 18%.
Scheme 25. Nitrogen CeH insertion at C13 of a saturated mutilin derivative by Berner. Reagents: a. COCl2, py; b. n-Bu4N$HSO4, NaN3, 94%; c. CCl4, 140 C, sealed tube, 28%; d. ZnCl2,
HCl, 87%.
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e6930 6921106 or 107 to access the C13 amino derivative were unsuccessful
under basic or mildly acidic conditions. Treatment of 107 with
concentrated HCl at 100 C afforded the novel rearranged product
110; the proposedmechanism involved protonation of the alkene to
form 108, methyl migration and ring contraction to form keto al-
dehyde 109, which underwent aldol reaction and oxazolidinone
hydrolysis to form 110.Scheme 27. Anionic oxy-cope approach to pleuromutilin core by Kahn. (A) Synthetic plan; (B) model study. Reagents: (B) a. cyclopropyl(phenyl)sulﬁde, BuLi; b. HBF4, 58% (two
steps); c. CH2CHMgBr; d. KH, 35% (two steps); e. H2N2; f. CrO3, H2SO4, 88% (two steps).Formation of the C13e14 fused oxazolidinone has been reported
using two different routes. Uccello at Pﬁzer has reported conditions
compatible with the C12 vinyl group, however, a scalable procedure
for the hydrolysis to C13 amino pleuromutilin has yet to be
reported.3. Synthetic approaches towards pleuromutilin
Alongside synthetic modiﬁcation of pleuromutilin, intense ef-
fort has focused on access to synthetic cores. This has led to sixdistinct approaches to the core, three of which relate to complete
total syntheses.
Kahn ﬁrst investigated synthetic access to the core of pleuro-
mutilin in 1980,124 proposing that the addition of a vinyl anion
fragment to spirocyclobutanone 113 and oxy-Cope rearrangement
would deliver the skeleton of the natural product 111
(Scheme 27A).A model study based on forming the 6,8 ring system was un-
dertaken (Scheme 27B). Spiroannulation of cyclohexenone 115
according to the procedure of Trost125 gave the spirocyclobutanone
116. Addition of vinyl magnesium bromide to the carbonyl group
afforded the tertiary allylic alcohol 117, which underwent the de-
sired oxy-Cope [3,3] sigmatropic rearrangement to give the 6,8 ring
system 118 in 35% yield. Subsequent diimide reduction of both the
alkene and carbonyl group followed by Jones oxidation gave 119
(Scheme 27B).
In the mid and late 1980s Paquette and co-workers identiﬁed
advanced intermediates in a proposed asymmetric pleuromutilin
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e69306922synthesis through degradation studies (Scheme 28A).126e130 The
group identiﬁed the degradation product 122 and presented
a synthetic approach to this lactone, which was then successfully
converted into the bicyclic diketone 133 (Scheme 28B). Although
this advanced intermediate bore all 20 carbon atoms of the pleu-
romutilin framework attempts to reconstruct the cyclooctane ring
from 133 using a Michael addition were unsuccessful owing to the
kinetically unfavourable medium-ring forming cyclisation reaction.Scheme 28. Synthetic studies towards pleuromutilin using a relay approach by Paquette. Reagents: (A) a. PCC, 86%; b. KOH, EtOH, 83%; c. PCC; d. HS(CH2)2SH, p-TsOH, 47% (two
steps). (B) a. NaH, DMF, MeI, 81%; b. BrMgCCCH2OTHP, 71%; c. H2SO4, EtOH, 59%; d. HS(CH2)2SH, p-TsOH; e. DIBAL, 91% (two steps); f. OCNCH(CH3)Ph, DMAP, 128major 28%, 78% ee;
g. HSiCl3, Et3N, PhCH3; h. CrO3, py, 50% (two steps); i. BrMg(CH2)3C(OCH2)2, 47%; j. p-TsOH, acetone; k. CrO3, H2SO4; l. HS(CH2)2SH, p-TsOH, 58% (three steps); m. LDA, CH3CHO; n.
CH3SO2Cl, Et3N; o. DBU, 49% (three steps); p. i-PrN(Li)Cy; q. CH3I, HMPA, 36% (two steps); r. DIBAL; s. HS(CH2)2SH, AlCl3, 58% (two steps); t. MeLi; MeI, 90%; u. MeI, H2O, 38%; v.
EtMgBr, 47%; w. PCC, 99%.A successful synthetic approach to the tricyclic core of pleuro-
mutilin was published by Zard and co-workers in 2003.131 Noting
the difﬁculties experienced by Paquette in forming the quaternary
centre at C9 at a late stage in the synthesis, Zard proposed forma-
tion of a xanthate intermediate 141 (Scheme 29), which could un-
dergo an 8-endo-trig cyclisation.
In order to construct the ﬁrst cyclisation substrate 137 (Scheme
29), carboxylic acid 136 was prepared from m-ethyl toluate 134 in
three steps. From this, the acyl phenyl selenide 137was synthesised
in two steps via the corresponding acid chloride. Cyclisation of 137
gave the desired cis-hydrindanone 138 via 5-exo-trig cyclisation of
the acyl radical formed on heating 137 at reﬂux in heptane in the
presence of catalytic ACCN, followed by trapping of the resultant
radical with allyltributyltin.
The methylketone 140 was formed from 138 in two steps
according to the protocol outlined in Scheme 29. Bromination of
the silyl enol ether of 140 was followed by the formation of O-
ethyl xanthate 141, which underwent 8-endo-trig cyclisation
upon treatment with DLP in DCE thus completing a concise
construction of the pleuromutilin skeleton 142. Zard suggested
that the xanthate may offer a suitable handle for furtherfunctionalisation of the pleuromutilin core but also reported
cleavage of the xanthate in 80% yield by treating 142 with n-
Bu3SnH and catalytic AIBN.
The Procter group has reported two approaches to the pleuro-
mutilin core. The ﬁrst generation approach involved a SmI2-medi-
ated cyclisation of readily accessible aldehyde 146 to form the 5,6-
bicycle 147 and, after further elaboration, ring-closing metathesis
(RCM) gave access to the 5,6,8-tricyclic core 149 (Scheme 30).132e136Enone 144 was available from 3-ethoxy-2-cyclohexenone 143 in
two steps; alkylation and conjugate addition to 144 were followed
by trapping of the intermediate enolate with Comins’ reagent to
afford the vinyl triﬂate 145. Methoxycarbonylation, deprotection
and oxidation afforded the desired cyclisation substrate 146.
SmI2-mediated cyclisation proceeded with excellent diaster-
eoselectivity and highyield to afford cis-hydrindane 147. Themethyl
ester was converted to the allylic alcohol 148 which smoothly
underwent ring-closing metathesis with Grubbs’ second-genera-
tion catalyst to give 149. Procter reported further manipulation
of the core (149) towards analogues of pleuromutilin: installation of
a C12 vinyl group, oxidation to the ketone at C3 and addition of
the C14 glycolate ester afforded synthetic pleuromutilin analogue
151.
A second generation approach to pleuromutilin was reported by
Procter in 2009; this route gained access to the tricyclic core
through a SmI2-mediated cascade cyclisation, forming the ﬁve- and
eight-membered rings in a single step and setting four contiguous
stereocentres with exquisite diastereocontrol (Scheme 31).137 The
cascade cyclisation substrate 154 was constructed from 152 in six
steps. In this approach, an allyl silane was introduced through
Scheme 30. SmI2-mediated cyclisation, RCM approach to pleuromutilin core by Procter. Reagents: a. ClMg(CH2)3OMgBr; b. TBSCl, im, 66% (two steps); c. LDA, MeI; d. CH2]
CH(CH2)2MgBr, CuI; Comins’ reagent, 72% (two steps); e. Pd(OAc)2, CO, Ph3P, Et3N, MeOH; f. HF, py; g. (COCl)2, DMSO, Et3N, 78% (three steps); h. SmI2, t-BuOH, 80%; i. TBDPSCl, im; j.
DIBAL; k. (COCl)2, DMSO, Et3N, 72% (three steps); l. CH2CHMgBr, 89%; m. Grubbs’ II, 83%; n. DMP, 79%; o. CH2CHMgBr, 86%; p. DIBAL, 90%; q. AcOCH2C(O)Cl, Et3N; r. HF, py; s. TPAP,
NMO, 65% (three steps); t. K2CO3, MeOH, 91%. R¼TBDPS.
Scheme 31. SmI2-mediated cascade approach to the core of pleuromutilin by Procter. Reagents: a. TMSCH2C(MgBr)CH2, CuI; Comins’ reagent, 85%, 2.5:1 dr; b. Pd(OAc)2, PPh3, CO,
Et3N, MeOH, 88%, 2.5:1 dr; c. TBSO(CH2)2CHO, BF3$OEt2, TBAT, 75%, 2.5:2.5:1:1 dr; d. Ac2O, py, DMAP; e. HF, py; f. DMP, 90% (three steps), 2.5:2.5:1:1 dr; g. SmI2, t-BuOH, 86%,
2.5:2.5:1:1 dr; h. TBSOTf, Et3N, 94%; i. LiAlH4; j. DMP, 2.5:1 dr, major 64% (two steps); k. H2, Pd/C, 68%; l. 1,2-ethanediol, HC(OMe)3, amberlyst-15; m. LiAlH4, 83% (two steps); n.
CH3C(OCH3)2CH3, CSA; o. TBSOTf, DMAP, Et3N, 94% (two steps); p. PPTS, EtOH, 75%; q. NaH, MBzCl, 77%; r. TCDI; s. n-Bu3SnH, AIBN, 72% (two steps).
Scheme 29. Radical approach to the core of pleuromutilin by Zard. Reagents: a. Li, NH3, t-BuOH, Br(CH2)3OTHP; b. H2, ClRh(PPh3)3, 72% (two steps); c. CrO3, H2SO4, 80%; d. (COCl)2;
e. PhSeSePh, NaBH4, 75% (two steps); f. AllylSnBu3, ACCN, 55%; g. PTSA, CH3C(CH2OH)2CH3, HC(OEt)3, 85%; h. MeLi, 80%; i. LDA, TMSCl; j. NBS, NaHCO3; k. KSC(S)OEt, 80% (three
steps); l. DLP, 60%.
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e6930 6923conjugate addition. Methoxycarbonylation then afforded 153,
which underwent Sakurai allylation to install the remaining car-
bons of what would become the eight-membered ring. Finally
protecting group manipulation and bis-oxidation afforded the
dialdehyde 154. SmI2-mediated dialdehyde cascade cyclisation
proceeded to afford the 5,6,8-tricyclic core in high yield and
diastereoselectivity.Procter went on to report the synthesis of 159, a differentially
protected intermediate from Boeckman’s total synthesis. Key to the
conversion of 155 to 159 was the reduction and deoxygenation of
the methylester, this proceeded through the triol 157. A four-step
procedure for the processing of this triol to 158was developed and
deoxygenation according to the BartoneMcCombie procedure was
reported.
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e69306924Independently of the work of Procter and co-workers, Sorensen
reported a number of approaches to the core of pleuromutilin.
Sorensen reported two RCM approaches, either forming the
C12e13 or C11e12 bond of the eight-membered ring
(Scheme 32).138 The ﬁrst approach converted 160 to the cis-
hydrindanone 162 through a series of conjugate additions. Pro-
tection of the ketone was followed by borylation of the alkene and
palladium-catalysed cross-coupling to install the desired alkene
tether. The nitrile 162was converted to the a,b-unsaturated ketone
163 through a reduction, Grignard addition, oxidation procedure
(Scheme 32A). Formation of the eight-membered ring proceeded in
this approach in moderate 31e47% yield upon treatment of 163
with the Grubbs’ II catalyst.Scheme 32. Ring-closing metathesis approach to the tricyclic core of pleuromutilin by Sorensen. Reagents: (A) a. CH2CHMgBr, CuBr$Me2S, BF3$Et2O, 66%, 2:1 dr; b. HMDS, TMSI; c.
Pd(OAc)2, 68% (two steps); d. Et2AlCN, 89%; e. CH3C(CH2OH)2CH3, p-TsOH, 95%; f. 9-BBN; PdCl2(dppf), CsCO3, AsPh3, 2-bromopropene, 71%; g. DIBAL; h. CH2CHMgBr; i. DMP, 50%
(three steps); j. Grubbs’ II, CH2Cl2, 31e47%. (B) a. BrMg(CH2)3C(OCH2)2, CuBr$Me2S, DMAP, TMSCl; HCl, 61%; b. Et2AlCN; c. p-TsOH, ethylene glycol, 77% (two steps); d. DIBAL; e.
CH2C(CH3)CH2MgBr, 84% (two steps) 1:2 dr; f. 168 minor 33%, Ph3COCH2CO2H, DCC, DMAP, 95%; g. HoveydaeGrubbs’ II, 80%.Alternatively, formation of the C11e12 bond of the eight-
membered ring proceeded in 80% yield (Scheme 32B). In this case
the key intermediate was accessed through a conjugate addition
aldol cyclisation to form 166, followed by addition of cyanide to the
a,b-unsaturated ketone. Following protection of the ketone, re-
duction of the nitrile was followed by addition of methallyl
Grignard and protection using the desired glycolate derivative to
form 168. RCM using the HoveydaeGrubbs’ II catalyst gave access
to the core (169) in high yield.
Sorensenhas since reported analternativeNozakieHiyamaeKishi
(NHK) approach to the tricyclic core of pleuromutilin (Scheme 33A).
This route has been used to access the ﬁrst totally syntheticScheme 33. NHK approach to synthetic analogues of pleuromutilin by Sorensen. Reagents
lutidine; d. citric acid, NH4Cl, 71% (two steps); e. CBr4, PPh3, Et3N, 90%; f. DIBAL; g. CrCl2, 4pleuromutilin analogues that have been assessed for biological ac-
tivity (Scheme 33B).139,140 Excitingly, some of Sorensen’s simpliﬁed
analogues have comparable biological activity to pleuromutilin.
In this approach, common intermediate 167 was subjected to
ozonolysis to afford aldehyde 170. The NHK reactionwith protected
2-bromoallyl alcohol proceeded in high yield to give a mixture of
diastereoisomers (171), allowing later investigation of both epimers
at C11. Protecting group manipulation was followed by Appel bro-
mination and reduction of the nitrile to afford bromo-aldehyde 172,
which underwent intramolecular NHK reaction to form 173 in
moderate yield.
Sorensen has further elaborated 173 to investigate synthetic
pleuromutilin and tiamulin analogues; 177 was shown to be themost active analogue, exhibiting identical MIC values to tiamulin
against Mycobacterium tuberculosis mc27000. Interestingly this
compound is the unnatural epimer at C11.4. Total syntheses of pleuromutilin
Two racemic syntheses of pleuromutilin have been reported to
date; the ﬁrst by Gibbons was reported in 1982 and Boeckman
followed with his anionic oxy-Cope strategy in 1989. Most recently
in 2013, the ﬁrst non-racemic approach to (þ)-pleuromutilin was
reported by Procter.: (A) a. O3; PPh3, 91%; b. BrC(CH2OTES)]CH2, CrCl2, NiCl2, 75%, 1:1 dr; c. TBSOTf, 2,6-
8% (two steps), 2:1 dr. (B) R¼eCH2CH2N(Et)2.
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e6930 6925Gibbons’ approachwas based on the construction of a tetracyclic
intermediate 186 (Scheme 34), which could be accessed in 12
steps.141,142 The bridged cis-hydrindane ring system 180 was con-
structed via sequential Michael reaction of 178 and 179. A series of
organolithium additions and oxidations gave 182, which was hy-
drogenated to give 183 as a 3:1 mixture of diastereoisomers. Aldol
condensation of 183 gave 184, which was converted into the key
intermediate 186 through epoxidation, ring opening and protection
(Scheme 34).Scheme 34. Total synthesis of ()-pleuromutilin by Gibbons. Reagents: a. LDA, 62%; b. CH2CHLi, 67%; c. PCC, 79%; d. MeLi, 82%; e. MnO2, 88%; f. H2, 10% Pd/Al2O3, MgO, 61%; g.
K2CO3, 92%; h. POCl3, DMAP, py; i. TFA, 80% (two steps); j. t-BuOOH, VO(acac)2, 97%; k. t-BuOK, t-BuOH; l. KH, MOMCl, 71% (two steps); m. N-bromoacetamide, NaOAc; n. Zn, AcOH,
81% (two steps); o. DIBAL; p. MsCl, py; q. LiAlH4, 68% (three steps); r. PCC; s. Na, Na/Hg, 88% (two steps); t. MOMBr, i-Pr2NEt; u. O3; v. P(OMe)3, 95% (three steps); w. (Z)-[2-
ethoxyvinyl]lithium; x. H2SO4, 50% (two steps); y. DIBAL, 95%; z. CuI, MeLi, [n-Bu3PN(Me)Ph]þI, 50%; a0 . Li, NH3; b0 . PCC; c0 . HCl, 80% (three steps); d0 . AcOCH2COOH, MsCl,
DMAP, py; e0 . KOH, MeOH.With the key tetracyclic intermediate in hand, Gibbons had
proposed a retro-aldol reaction to afford the desired bond cleavage
to diketone 188. However, this reaction was unsuccessful and the
transformation was instead achieved via a Grob-type fragmenta-
tion promoted by N-bromoacetamide to form 187, which was fol-
lowed by a zinc-mediated reduction to diketone 188 (Scheme 34).
Gibbons then began the task of modifying the functionality on
the tricyclic core to complete the synthesis in a further 17 steps.
Removal of the carbonyl on the six-membered ring was achieved in
three steps by reduction to the diol, which was selectively mesy-
lated and reduced to afford 189. The stereochemistry at C14 at this
stage was opposite to the natural product and epimerisation was
achieved using an oxidation/reduction sequence. Protection and
ozonolysis of 190 gave 191 (Scheme 34); this key intermediate was
also used in the route of Boeckman’s group (vide infra, Scheme 35).Formation of the quaternary centre at C12 from ketone 191 was
the ﬁnal signiﬁcant challenge in the ﬁrst synthesis of pleuromutilin.
Gibbons stated that methods that formed a carbanion at C12 result
in elimination of the C11 hydroxyl and methods which relied upon
carbonium ion character at C12 also proved unsuccessful. Thus
Gibbons formed the a,b-unsaturated aldehyde and reduced it to the
allylic alcohol 192. g-Alkylation of 192 gave exclusively the desired
epimer 193 according to Murahashi’s procedure.143 Allylic alcohol
192 was recovered (20% yield) and the product resulting from a-alkylation was also formed (20% yield) in this key step.
The C3 carbonyl group was installed by benzyl deprotection
followed by oxidation. Cleavage of the methoxymethyl ether pro-
tecting groups completed the ﬁrst racemic total synthesis of
mutilin, which was converted to pleuromutilin by bis-glycolic ester
formation and mild hydrolysis (Scheme 34).
Boeckman proposed an approach to pleuromutilin involving the
construction of the tricyclic skeleton 199 devoid of most of the
required functionality and stereochemistry (Scheme 35). Elabora-
tion of this skeleton would then be carried out, with the relative
stereochemistry being controlled by the conformation of the ring
systems, as predicted by MM2 calculations.119,144e146
Boeckman envisioned formation of the tricyclic core via an oxy-
Cope rearrangement of bridged tricyclic intermediate 198. Dienone
196was formed byMichael addition/aldol condensation of 194 and
Scheme 35. Total synthesis of ()-pleuromutilin by Boeckman. Reagents: a. LDA, 61%; b. pyrrolidine; AcOH, NaOAc, 98%; c. AcOH; d. p-TsCl, DMAP, py, 74% (two steps); e. (Me)2CuLi;
HMPA, 93%; f. CH2CHMgBr, 198, 43%, minor epimer recycled, PhSCl; MeOH, P(OEt)3, 198 70% after two cycles; g. KH, 18-crown-6, 99%; h. m-CPBA; i. BF3$OEt2; (CH2OH)2, 89% (two
steps); j. Li, NH3; k. KH, BnBr, 69% (two steps); l. PyHBr3; m. t-BuOK, DMSO, 67% (two steps); n. p-TsOH, H2O, 67%; o. MOMCl, i-Pr2NEt, p. TMSI, HMDS; q. m-CPBA, NaHCO3; r. TBAF,
62% (four steps); s. MOMCl, i-Pr2NEt, 90%; t. CH2CHMgBr; u. SOCl2; v. MeCuB(Me)3, 50% (three steps); w. Li, NH3; x. PCC; y. HCl/EtOH, 80% (three steps); z. AcOCH2COOMs, DMAP; a0 .
KOH, MeOH, 39% (two steps).
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e69306926195 (Scheme 35). Following functional groupmanipulation, tricycle
197 was formed via 1,6-conjugate addition/intramolecular enolate
alkylation. Addition of vinyl Grignard to 197 proceeded with no
stereochemical preference; the desired epimer 198 was isolated in
43% yield and the undesired diastereoisomer was equilibrated to
a mixture of diastereoisomers (dr 1:1) by treatment with phenyl-
sulfenyl chloride and triethylphosphite in methanol. The pleuro-
mutilin skeleton 199 was successfully formed via an anionic oxy-
Cope rearrangement of 198 in exceptionally high yield (Scheme 35).
Following the synthesis of 199, studies to introduce the required
functionality began. Epoxidation of 199 was followed by rear-
rangement to install the C3 carbonyl and subsequent ketalization
gave 200. The C3 carbonyl group was reduced and protected as the
benzyl ether before treatment with PyHBr3 afforded the equatorial
bromo-ketal, this underwent syn-elimination to the E-alkene 202.
Treatment of 202with p-toluenesulfonic acid inwet acetone heated
to reﬂux installed the C14 hydroxyl, which was protected as the
MOM ether 203.
Extensive work was carried out on the optimisation of C11 ox-
idation to form 191.119 The formation of silyl enol ethers using ei-
ther TMSCl and LDA or TBSOTf and Et3N both gave mixtures of silyl
enol ethers and therefore upon epoxidation and rearrangementFig. 3. Studies on the construction of the C12mixtures of C11 and C13 silyloxy products. However, the conditions
shown in Scheme 35 for the Rubottom-type oxidation selectively
installed the C11 hydroxyl as a single epimer. Protection as the
MOM ether gave access to Gibbons’ intermediate 191 (vide supra,
Scheme 34).
At this stage the development of methods for the introduction of
the quaternary centre at C12 from ketone 191 began. To provide
additional material to carry out their studies, a route to 191 from
natural mutilinwas developed (vide supra, Scheme 22); this seven-
step protocol provided sufﬁcient material to develop the ﬁnal steps
of the synthesis before carrying out the transformations only once
on valuable, totally synthetic material.
Simpliﬁed model studies for a Wittig-based route looked
promising, however, noWittig reactionwas successfully carried out
on 191; the C12 carbonyl is believed to be too sterically crowded.
Addition of vinyl Grignard to 191 followed by treatment of the
resultant, inconsequential 7:1 diastereoisomeric mixture of allylic
alcohols with thionyl chloride and triethylamine gave allylic chlo-
ride 204. Initially Boeckman proposed access to 193 by cyclo-
propanation and rearrangement of an allylic silane, however,
attempts to convert 204 to the allylic silane resulted in g-addition
of silicon to give 205 (Fig. 3).methyl vinyl stereocentre by Boeckman.
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e6930 6927The possibility of g-alkylation of 204 was next investigated.
Addition of lithium dimethylcuprate to 204 yielded a 2.6:1 mixture
of a-alkylation product 207 and diene 206 (Fig. 3). No g-alkylationScheme 36. Total synthesis of (þ)-pleuromutilin by Procter. Reagents: a. BrMgCH2CH2CH2OTBS, CuCN$2LiCl, TMSCl; b. Pd(OAc)2, O2, 85% (two steps); c. TMSCH2C(MgBr)CH2, CuI;
Comins’ reagent, 85%, 2.5:1 dr; d. Pd(OAc)2, PPh3, CO, MeOH, Et3N, 85%, 2.5:1 dr; e. TBSOCH2CH2CHO, BF3$OEt2, TBAT, 73%, 2.5:2.5:1:1 dr; f. PivCl, py, DMAP; g. HF, py; h. DMP, 88%
(three steps), 2.5:2.5:1:1 dr; i. SmI2, t-BuOH, 88%, 2.5:2.5:1:1 dr; j. TBSOTf, Et3N, 76%, 2.5:2.5:1:1 dr; k. LiAlH4; l. DMP, 63%, >98:2 dr, >98% ee; m. H2, Pd/C, 75%; n. 1,2-ethanediol,
HC(OMe)3, Amberlyst 15, 96%; o. SmI2, pyrrolidine, H2O, 95%; p. LDA, MBzCl, 77%; q. TCDI; r. nBu3SnH, AIBN, 66% (two steps); s. FeCl3$SiO2, 99%; t. TMSI, HMDS; u. m-CPBA,
NaHCO3; v. TBAF, 94% (three steps); w. HF, 78%; x. MOMCl, DIPEA, 75%; y. EtOCHCHSnBu3, n-BuLi; z. FeCl3$SiO2; a0 . NaBH4, H2O, 63% (three steps); b0 . NCS, DMS, 97%; c0 . CuCN,
Me2Zn, 71%; d0 . LiAlH4; e0 . DMP; f0 . AcCl, EtOH, 69% (three steps); g0 . triﬂuoroacetylimidazole; h0 . triﬂuoroacetoxyacetic acid, EDCI, DMAP; MeOH, Et3N, 75% (two steps).product was observed. Addition of lithium cyano(methyl) cuprate
in HMPA and THF gave the desired g-alkylation product 193 as the
major product in a 2:1:1 mixture with 206 and 207, respectively.
Alkylation with a 1:1 complex of methyl copper and triethyl boron
had been reported by Yamamoto et al.147 and gave exclusively g-
alkylation, however in this system a 1.8:1 mixture of ethyl and
methyl addition was observed. Finally treatment of allylic chloride
204 with CH3CuB(CH3)3 afforded a 5:1 mixture of 193 and 207 in
93% yield.
At this stage attention was turned to conversion of 193 to
mutilin (2) and ultimately to pleuromutilin (1). Mutilin was used to
produce protected triol 193, such that these ﬁnal steps could be
investigated. Despite this investigation and the construction of
differentially protected analogues of 193, Boeckman found Gibbons’
endgame to provide the best approach to pleuromutilin.
In 2013 Procter reported the ﬁrst non-racemic synthesis of
(þ)-pleuromutilin. The key steps of the synthesis are the SmI2-
mediated cascade cyclisation to form the 5,6,8-tricyclic core and
the SmI2eamineeH2O-mediated reduction of a very hinderedmethyl ester. Non-racemic cascade substrate 213 was available
from the chiral pool starting material 208 in eight steps according
to the procedure shown in Scheme 36.148A series of conjugate additions were followed by methox-
ycarbonylation of a vinyl triﬂate to afford 210 as a 2.5:1 mixture of
diastereoisomers. Sakurai allylation was used to install the
remaining carbons required for the cascade substrate and pro-
tecting groupmanipulation and oxidation gave 213; in this case the
pivaloyl protection was reported to give a more stable dialdehyde.
SmI2-mediated cascade cyclisation of 213 proceeded in excellent
yield and with very high diastereocontrol to give the desired tri-
cyclic core of pleuromutilin 214.
Following protecting group manipulation and oxidation of 214,
ketone 215 was reported as a single diastereoisomer and enantio-
mer in >98% ee. Reduction of the oleﬁn 215 proceeded in near
quantitative yield to give a separable 3:1 mixture of di-
astereoisomers; the major ketone 216 was protected with con-
comitant removal of one silyl ether to give 217. SmI2eamineeH2O-
mediated reduction of 217 proceeded in 95% yield using pyrrolidine
as a crucial, activating Lewis basic additive.149 Selective protection
of the resultant diol was reported to form 218. This route avoided
the protecting group chemistry necessary to process triol 157 (vide
N.J. Fazakerley, D.J. Procter / Tetrahedron 70 (2014) 6911e69306928supra, Scheme 31). Procter then reported the deoxygenation of 218
to afford 219 via the thioimidazolide according to the Bar-
toneMcCombie procedure.
Following deprotection of the ketal, Rubottom oxidation
according to the procedure of Boeckman installed the C11 hydroxyl
both regio- and diastereoselectively to give 220. The authors where
unable to construct the C12 methyl, vinyl stereocentre in the
presence of the C14 silyl ether and also reported lower selectivity
for the Rubottom oxidation with MOM protection on the C14 hy-
droxyl, in line with the observations of Boeckman. They therefore
converted 220 to the bis-MOM ether 221 in two steps and con-
structed the methyl, vinyl stereocentre by a modiﬁcation of both
the Gibbons and Boeckman methods. Allylic chloride 222 was, in
this case, constructed by addition of a lithiated enol ether to ketone
221, the inconsequential mixture of diastereoisomers was hydro-
lysed to the a,b-unsaturated aldehyde, which was then reduced to
the allylic alcohol before CoreyeKim chlorination gave 222. SN20
Alkylation of 222 was achieved using Me2Zn and CuCN in DMF,
delivering the methyl both regio- and diastereoselectively to form
223 in 71% yield.
Progression of 223 to (þ)-mutilin (2) was described in three
steps according to standard procedures that are shown in Scheme
36. Efﬁcient conversion of mutilin (2) to pleuromutilin (1) was
previously unreported in the literature. The Gibbons approach re-
lied upon multiple iterations and the yield reported by Boeckman
was low (39%). The use of C11 triﬂuoroacetate protection was,
however, known for the synthesis of C14 analogues of pleuro-
mutilin and the group of Procter utilised this methodology to ﬁnish
the total synthesis. Treatment of (þ)-mutilin (2) with tri-
ﬂuoroacetylimidazole at reduced temperature gave C11 tri-
ﬂuoroacetylmutilin, which underwent efﬁcient EDCI coupling with
triﬂuoroacetoxyacetic acid. It was shown that quenching the re-
action with methanol and treatment with triethylamine led to the
cleavage of both triﬂuoroacetate groups and delivered (þ)-pleu-
romutilin (1) in 75% for the last two steps.
To date three strategically very different total syntheses of
pleuromutilin have been reported, with surprisingly similar step
counts. Each offers different insights into the construction and
functionalisation of this unique and beautiful natural product.
Gibbons’ fragmentation approach elegantly constructs a highly
functionalised tricyclic core, which is further elaborated to the
natural product in a total of 31 steps. Boeckman’s route, by far the
shortest (27 steps), relies upon late stage functionalisation of
a largely unfunctionalised core constructed by a [3,3]-sigmatropic
rearrangement. Importantly, the work of Boeckman’s group has
taught the community much about the functionalisation of the
core, through experimentation and calculation. Procter’s syn-
thesis is the ﬁrst to gain access to (þ)-pleuromutilin and involves
a remarkable cascade cyclisation constructing four contiguous
stereocentres and two new rings in a single step, the group went
on to report the ﬁrst efﬁcient conversion of mutilin to
pleuromutilin.5. Conclusions
Industrialists and academics alike have been inspired by
pleuromutilin since its ﬁrst isolation 63 years ago, yet, only three
pleuromutilin derivatives grace the market. A vast amount is now
understood about the SAR surrounding the C14 side chain and
semi-synthesis has provided some modiﬁcations to the core.
However, these efforts have not resulted in new treatments.
Semi-synthetic analogues are still under investigation and syn-
thetic approaches to the core, reported over the last 5 years,
promise to offer novel totally synthetic analogues, which maybecome key weapons in the ongoing battle against antimicrobial
resistance.
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